Patient Preference Integration Lead
Pfizer, Inc.
Disclosure(s): Pfizer Inc: Stocks/Bonds (Private Company)
Brett Hauber, PhD, is Patient Preference Evidence Integration Lead in the Patient-Centered Research and Partnership group at Pfizer. He is also Affiliate Associate Professor in the Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington School of Pharmacy. Within Pfizer, Brett serves as the lead Patient Preference Studies subject-matter expert. He is co-chair of the Patient Preference Studies Technical Advisory Committee (TAC), co-Chair of the Benefit-Risk Advisory Council (BRAC), and Pfizer’s representative to the PhRMA Patient Focused Drug Development (PFDD) Working Group. Brett is the Deputy Topic Lead representing PhRMA on the ICH E22 Expert Working Group developing global guidelines for the General Considerations for Patient Preference Studies. Brett is also the industry lead for the Innovative Health Initiative (IHI) public-private partnership project for Patient-Centred Clinical-Study Endpoints Derived Using Digital Health Technologies.
Prior to Pfizer, Brett was a Senior Fellow and the Vice President of Health Preference Assessment at RTI Health Solutions. Brett was actively involved in the IMI PREFER project. He is past Benefit-Risk co-chair of the Benefit-Risk Assessment Communication and Evaluation (BRACE) special interest group of the International Society for Pharmacoepidemiology (ISPE). He has sat on the Editorial Boards of Pharmacoeconomics and The Patient. He was the Principal Investigator on the Catalogue of Patient Preference Methods developed by the Medical Device Innovation Consortium in 2015. He has been a member of multiple ISPOR Task Forces developing good research practices for preference elicitation and was the Chair of the ISPOR Task Force for Good Research Practices for the Statistical Analysis of Discrete-Choice Experiments.